BridgeMD
New treatment option for Uterine Cervical Neoplasms
Official title Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy
ClinicalTrials.gov ID: NCT06509724
What this study is testing
- What it's testing
- Radical hysterectomy and radiation therapy are standard treatments for cervical cancer. However, there are no reported studies on the frequency of side effects and treatment outcomes when hypofractionated radiation therapy and intensity modulated radiation therapy(IMRT) are used during radiation therapy.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 75, women only
You may be able to join if
- Patients diagnosed histologically with cervical cancer
- Patients diagnosed histologically with Squamous cell carcinoma, Adenocarcinoma, or Adenosquamous carcinoma
- Patients who have undergone radical hysterectomy and pelvic lymphadenectomy
- Patients who meet the indication for radiotherapy in postoperative pathological examination (at least on of the following): A. Pelvic lymph node...
- Adult aged 20 to 75 years
You likely can't join if
- Patients with distance metastasis (including ovarian and para-aortic lymph node metastasis)
- Patients who have previously received radiotherapy to the pelvic area
- Patients who have undergone radical hysterectomy more than 3 months prior
- Patients with untreated serious acute illnesses (e.g., stroke, cerebral infarction, myocardial infarction) other than cervical cancer
- Patients who received neoadjuvant chemotherapy before surgery
- Patients who will not receive concurrent chemotherapy during radiotherapy
See the full eligibility criteria
- Patients diagnosed histologically with cervical cancer
- Patients diagnosed histologically with Squamous cell carcinoma, Adenocarcinoma, or Adenosquamous carcinoma
- Patients who have undergone radical hysterectomy and pelvic lymphadenectomy
- Patients who meet the indication for radiotherapy in postoperative pathological examination (at least on of the following): A. Pelvic lymph node metastasis B. Parametrial involvement C. Positive surgical margins
- Adult aged 20 to 75 years
- Patients with an ECOG 0-1 within 1 week prior to study participation
- Maintained bone marrow function: granulocyte ≥1.0 x 103/µl, platelets ≥30 x 103/µl, hemoglobin ≥9.5 g/dl
- Maintained renal and liver function (Creatinine \<2.0 mg/dL, Bilirubin \< 1.5 mg/dl)
- Patients who have voluntarily signed the consent form
- Patients with distance metastasis (including ovarian and para-aortic lymph node metastasis)
- Patients who have previously received radiotherapy to the pelvic area
- Patients who have undergone radical hysterectomy more than 3 months prior
- Patients with untreated serious acute illnesses (e.g., stroke, cerebral infarction, myocardial infarction) other than cervical cancer
- Patients who received neoadjuvant chemotherapy before surgery
- Patients who will not receive concurrent chemotherapy during radiotherapy
- Patients with a history of another cancer diagnosis within the past 5 years, except for thyroid cancer, skin cancer, or carcinoma in suit
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, Gangnam-gu, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 20 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, Gangnam-gu, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.